The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The race against the clock continues. BIOT says it has enough votes for its merger with Blade Therapeutics, but needs more time to close. And the rest of the day’s news in SPACs.
The Branson-backed sustainable consumer goods company reports soft Q1 results ahead of 6.14 merger vote. June’s going to be a nail biter– a slew of extension and merger votes coming up.
An oversaturated SPAC market yields a combination of terminations and extensions as deal pressure intensifies. And the rest of the day’s news in SPACs.
Inflation, rising interest rates, and reduced corporate earnings across the board have led to persistent market gyrations which prove its too early for bottom fishing. The stampede out of deSPACs now makes it ‘deal-or-die’ time for those without targets.
